

AD_____

Award Number: DAMD17-98-1-8230

TITLE: Role of the Wnt-4 Protein in the Mouse Mammary Gland

PRINCIPAL INVESTIGATOR: Louise J. Huber, Ph.D.
Lewis A. Chodosh, Ph.D.

CONTRACTING ORGANIZATION: University of Pennsylvania
Philadelphia, Pennsylvania 19104-3246

REPORT DATE: July 2001

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20020910 077

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 074-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503				
1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE July 2001		3. REPORT TYPE AND DATES COVERED Final (01 Jul 98 - 30 Jun 01)
4. TITLE AND SUBTITLE Role of the Wnt-4 Protein in the Mouse Mammary Gland			5. FUNDING NUMBERS DAMD17-98-1-8230	
6. AUTHOR(S) Louise J. Huber, Ph.D. Lewis A. Chodosh, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Pennsylvania Philadelphia, Pennsylvania 19104-3246 E-Mail: lj_huber@hotmail.com			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES Report contains color				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) Germline mutations in <i>BRCA1</i> are the most common cause of familial breast cancer. In addition to full length <i>BRCA1</i> , both human and mouse cells express an alternatively spliced variant, <i>BRCA1-Δ11</i> that lacks exon 11 in its entirety. The finding that murine embryos bearing homozygous deletions of exon 11 of <i>Brcal</i> survive longer than embryos that are homozygous for null alleles suggests that exon 11-deleted isoforms may perform at least some of the functions of <i>Brcal</i> . To resolve this apparent inconsistency, and to address the functions of exon 11-deleted isoforms of <i>Brcal</i> , we have analyzed the <i>Brcal</i> protein in cells derived from a murine model in which only the exon 11-deleted <i>Brcal</i> isoform is expressed. Our results demonstrate that mouse <i>Brcal</i> is identical to human <i>BRCA1</i> with respect to its cell cycle regulation, DNA damage-induced phosphorylation, nuclear localization, and association with Rad51. We show that endogenous exon 11-deleted isoforms of <i>Brcal</i> localize to discrete nuclear foci indistinguishable from those found in wild type cells, despite the fact that they lack previously defined nuclear localization signals encoded in exon 11. We show that exon 11-deleted <i>Brcal</i> is not phosphorylated in response to DNA damage, unlike full length <i>Brcal</i> , and that γ-irradiation-induced Rad51 foci formation is significantly reduced in cells expressing only the exon 11-deleted isoform.				
14. SUBJECT TERMS Brcal isoform, DNA damage, breast cancer				15. NUMBER OF PAGES 38
				16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

(3) Table of Contents

Page 1	(1) Front Cover
Page 2	(2) Standard Form (SF) 298
Page 3	(3) Table of Contents
Page 4-5	(4) Introduction
Page 6-19	(5) Body
Page 20	(6) Key Research Accomplishments
Page 21	(7) Reportable Outcomes
Page 22-25	(8) Conclusions
Page 26-27	(9) References

Appendix

(4) INTRODUCTION

Initial reports describing the subcellular localization of BRCA1 were highly controversial. BRCA1 has been reported by different groups to localize to the cytoplasm, to the nucleus, to cytoplasmic tube-like invaginations in the nucleus, or to be secreted. These reports preceded experiments demonstrating functional roles for BRCA1 in DNA damage and transcription, each of which would have suggested that BRCA1 was likely to reside in the nucleus. Indeed, the subsequent observation that BRCA1 compartmentalizes to nuclear foci during S phase and undergoes a DNA damage-dependent dynamic redistribution served to focus efforts on experiments designed to identify a nuclear role for BRCA1.

In contrast to BRCA1, the properties and functions of the exon 11-deleted isoforms of BRCA1 are largely unknown. Previous experiments suggesting that BRCA1-Δ11 is localized to the cytoplasm were based on transient transfection protocols. Transient transfection methods have also been used to suggest that the murine counterpart to p110^{BRCA1} is localized predominantly in the cytoplasm. However, the fact that similar approaches indicated a cytoplasmic localization for p220^{BRCA1} suggests that determining the localization of exon 11-deleted isoforms will require examination of their endogenous expression patterns. Inconclusive results have been obtained regarding the cellular localization of p110^{BRCA1}; biochemical fractionation of transiently transfected cells has shown that p110^{BRCA1} is distributed equally between nuclear and cytoplasmic fractions whereas immunofluorescence analysis of the same ectopically expressed protein was reported to yield exclusively cytoplasmic staining. These reports appear to be at odds with studies of endogenous BRCA1 proteins that use BRCA1 antibodies that recognize determinants shared by full length BRCA1 and its isoforms, since these studies have generally failed to reveal the presence of BRCA1 proteins in the cytoplasm.

Notably, murine embryos bearing targeted mutations that selectively abolish expression of full length Brcal, while leaving Brcal-Δ11 expression intact, survive significantly longer than mice bearing targeted mutations that abolish expression of both Brcal and Brcal-Δ11. This finding suggests that in mouse cells Brcal-Δ11 is able to partially compensate for the functions of full length Brcal. Despite the decreased severity of their associated embryonic phenotype, embryonic cells derived from mice engineered to express only Brcal-Δ11 exhibit hypersensitivity to γ-irradiation, defective G2-M checkpoint function, centrosome amplification, and genomic instability. Furthermore, mice bearing mammary-specific deletions of exon 11 develop mammary

adenocarcinomas with chromosomal instability. These data suggest that while Brcal- Δ 11 may partially compensate for Brcal function during embryogenesis, this naturally occurring isoform lacks the ability to maintain genomic stability and suppress tumorigenesis.

In this report we demonstrate by biochemical fractionation and immunofluorescence that full length and exon 11-deleted isoforms of murine Brcal are cell cycle regulated and compartmentalize to nuclear foci during S phase. In contrast to full length Brcal, we show that Brcal-D11 is not phosphorylated in response to DNA damage, is deficient in its ability to bind to Rad51, and is unable to promote the efficient formation of Rad51 foci. Taken together, these data suggest that Brcal- Δ 11 may provide some of the functions of full length Brcal during murine embryogenesis, but is unable to fully supplant the functions of full length Brcal in the response to DNA damage.

(5) BODY

SPECIFIC AIM 1. GENERATION OF A TRANSGENIC MOUSE THAT EXPRESSES HUMAN BRCA1.

As described in the report submitted last year bitransgenic animals carrying a transgene that consists of the cyclin E promoter to direct expression of human *Brcal* were to be crossed with a murine *Brcal* knockout line. Embryos derived from crosses that would yield the presence of the transgene in a knockout background were screened to determine if the expression of the human *Brcal* protein had rescued the murine knockout embryos from lethality. In spite of the presence of the human *Brcal* transgene embryonic lethality occurred in a manner that was indistinguishable from knockout embryos that lacked the presence of the transgene. Immunoblot analysis of embryos harboring the transgene as well as cells cultured from these embryos failed to detect the presence of human *Brcal* protein.

SPECIFIC AIM 2. IDENTIFICATION OF GENES REGULATED BY MURINE BRCA1 EXPRESSION.

As described in the last year's annual report, mRNA derived from wild-type and *Brcal* exon 11 deficient fibroblasts in the absence and presence of γ -irradiation was to be analyzed for differential gene expression. Independent sample sets did not reveal consistent patterns of gene expression within the same sample and were we were unable to make comparisons between untreated and treated wild-type and knockout samples. The discrepancies that we encountered are likely to have been the result of variability in the cell populations due to cellular senescence. In conclusion we were unable to obtain additional samples in order to determine the optimal conditions for this experiment. It is likely that cell viability was affected during freezing and thawing of the cells since we observed on numerous occasions significant cell death upon thawing the knockout cell lines.

SPECIFIC AIM 3. CHARACTERIZATION OF BRCA1 EXON 11-DEFICIENT FIBROBLASTS.

Characterization of Mouse *Brcal* Antisera. Immunoblotting analysis of HC11 murine mammary epithelial cell extracts using murine *Brcal* antibodies mAb1, mAb2, mAb3, and mAb4, identified a specific band that migrated at a predicted molecular weight of 210 kDa and that was not recognized by preimmune sera (data not shown). To confirm that these antibodies recognize bona fide mouse *Brcal*, 293T cells were transfected with a mouse *Brcal* cDNA and lysates were prepared for immunoblotting. These studies revealed that polyclonal antibodies mAb1, mAb2, mAb3, and mAb4 each recognize a specific band at the predicted molecular weight

for mouse *Brcal* in extracts of *Brcal*-transfected 293T cells. (Fig. 1A and data not shown).

To determine if mAb1 could specifically recognize endogenous *Brcal*, extracts from wild-type mouse embryo fibroblasts (MEFs) and from MEFs derived from mice harboring a germline deletion of the exon 11 region of *Brcal* were analyzed by immunoblotting. *Brcal*^{-11/-11} MEFs express an isoform of *Brcal* analogous to the naturally occurring human BRCA1 variant encoding p97^{BRCA1}. Northern analysis was performed using a probe encompassing nucleotides 4827-5354 that was predicted to recognize both the full length and exon 11-deleted *Brcal* transcripts. As expected, a 3.9 kB transcript was detected in *Brcal*^{Δ11/Δ11} cells whereas a 7.2 kB transcript was detected in cells that express p210^{Brcal} (Fig.1B, left panel). A similar analysis performed with a probe encompassing nucleotides 2541-3298 within exon 11 detected only the full length *Brcal* transcript (Fig.1B, right panel). Accordingly, immunoblotting of extracts prepared from wild type MEFs revealed the presence of p210^{Brcal} whereas extracts prepared from *Brcal*^{Δ11/Δ11} MEFs did not, confirming that the 210 kDa polypeptide recognized by mAb1 is indeed *Brcal* (Fig. 1C). To determine if the putative protein encoded by the exon 11-deleted transcript is detectable in extracts derived from *Brcal*^{Δ11/Δ11} MEFs immunoblotting was performed. A major band of the predicted molecular weight, referred to here as p92^{Brcal}, was recognized by mAb1 antisera (Fig. 1D). This *Brcal* isoform was also detected in embryonic brain extracts prepared from embryos heterozygous for the exon 11-deleted allele of *Brcal*, as well as in extracts of testis and brain derived from wild type mice. These findings demonstrate that p92^{Brcal} is a naturally occurring isoform of *Brcal* (Fig 1E).




Figure 1. Detection of mouse *Brca1* isoforms. A) Immunoblot analysis demonstrating that mAb1, mAb2, and mAb4 recognize murine *Brca1*. 10 μ g of either empty vector (pBKCMV) or pBKCMV*Brca1* (mAb1) and pcDNA3.1 or pcDNA3.1-m*Brca1* (mAb2 and mAb4) was introduced into 293T cells by calcium phosphate transfection. (-) indicates empty vector and (+) indicates vector containing murine *Brca1* cDNA. Cell extracts were prepared 48 hrs following transfection and 50 μ g of lysate was used for immunoblotting. Affinity purified antibodies were employed at 1 μ g/ml. B) Northern analysis demonstrating the absence of full length *Brca1* transcripts in *Brca1* $^{\Delta 11/\Delta 11}$ MEFs. 10 μ g of polyA mRNA was loaded per lane. Probes encompassing exon 11-specific sequences (right panel and Materials and Methods) and C-terminal sequences (left panel and Materials and Methods) were derived by PCR amplification using the mouse *Brca1* cDNA as a template. C) Immunoblot analysis of p210^{*Brca1*} expression in wild-type and *Brca1* $^{\Delta 11/\Delta 11}$ MEFs. 50 μ grams of cell extract per lane was probed with affinity purified

mAb1 at 1 μ g/ml. D) mAb1 recognizes a predominant gene product of ~ 92 kDa in $Brcal^{\Delta 11/\Delta 11}$ MEFs and 210 kDa in HC11 cells. 30 μ grams of extract was loaded per lane. E) $p92^{Brcal}$ is expressed in testis and brain of wild-type mice. 150 μ g of lysate per sample was subjected to SDS-PAGE on an 8% gel. $\Delta 11/+Brain$ indicates tissue derived from a mouse heterozygous for the wild-type and exon 11-deleted alleles of *Brcal*.

Full length Murine $p210^{Brcal}$ and $p92^{Brcal}$ are Cell Cycle Regulated.

Previous experiments have shown that murine *Brcal* mRNA expression is regulated in a cell cycle-dependent manner with maximal levels of *Brcal* occurring during S phase of the cell cycle [1]. Human *BRCA1* mRNA and protein share this cell cycle-dependent pattern of expression consistent with a conserved S phase-specific function for the human and mouse *Brcal* proteins. To determine if the protein expression pattern of *Brcal* parallels that of its mRNA, synchronization experiments were performed using HC11 murine mammary epithelial cells. As shown in Fig. 2A, the mouse *Brcal* protein, $p210^{Brcal}$, is undetectable in serum starved cells and becomes apparent when cells have progressed into the G1 phase of the cell cycle approximately 8 hours following addition of serum containing media. Parallel experiments performed on $Brcal^{-11/+11}$ fibroblasts demonstrated that the cell cycle-dependent expression pattern of $p92^{Brcal}$ closely mimics that of $p210^{Brcal}$. Moreover, the temporal profile of $p92^{Brcal}$ and $p210^{Brcal}$ expression is similar to that of Rad51 and Cyclin A, but contrasts with that of Rad50 which is expressed at relatively constant levels throughout the cell cycle.




Figure 2. Mouse p210^{Brca1} and p92^{Brca1} are cell cycle regulated.

A) Immunoblot analysis of cell cycle regulation of p210^{Brca1}, Cyclin A, and Rad51 in serum-starved HC11 cells. B) Immunoblot analysis of cell cycle regulation of p92^{Brca1}, Cyclin A, and Rad51 in serum-starved mouse embryonic fibroblasts homozygous for the targeted deletion of exon 11. Cells were starved as described in Materials and Methods. Cells stimulated to reenter the cell cycle by refeeding were harvested at the time points indicated. Active refers to exponentially growing cells. Cell extracts were prepared as described in Materials and Methods and 10 µg of lysate was loaded per lane. Antibodies mAb1 and mAb2 revealed identical results in HC11 cells whereas only mAb1 recognized a cell cycle regulated band in Brca1^{Δ11/Δ11} MEFs (data not shown).

Phosphorylation of p92^{Brca1} is not Detected in Response to DNA Damage. The phosphorylation of human p220^{BRCA1} following treatment of cells with DNA damaging agents was an early indication that human BRCA1 is involved in a DNA damage response pathway. Similarly, immunoblotting analysis of lysates generated from HC11 cells one hour following treatment with UV, γ-radiation, or HU revealed a dose-dependent shift in the migration of full length murine Brca1 by SDS-PAGE (Fig. 3A, top panel). A complete shift of p210^{Brca1} similar to that described for human BRCA1 occurred in cells treated with 50 Gy.

³²P-orthophosphate labeling of HC11 cells following treatment with 5 Gy demonstrated an increase in p210^{Brca1} labeling consistent with the supposition that, similar to human BRCA1, the observed mobility shift is due to phosphorylation (Fig. 3B, top panel). Exposure of cells to ³²P-orthophosphate has previously been shown to cause an increase in phosphorylation of human BRCA1. Therefore, the basal levels of phosphorylation observed in unirradiated HC11 cells may be due either to the activation of a DNA damage response pathway by ³²P itself, or to cell cycle-dependent phosphorylation of Brca1. Significantly, a shift in p92^{Brca1} was not observed in response to identical treatments with DNA damaging agents suggesting that this isoform may not be phosphorylated under these conditions (Fig 3A, bottom panel). This possibility was confirmed by ³²P-orthophosphate labeling experiments in which increased phosphorylation of p92^{Brca1} was not detected following treatment of cells with 20-50 Gy (Fig 3B, bottom panel and data not shown).

Since the inability to detect a change in the phosphorylation status of p92^{Brca1} following DNA damage could be due to altered kinase signaling in Brca1^{Δ11/Δ11} fibroblasts rather than to properties specific to p92^{Brca1}, a p92^{Brca1} expression vector was transiently transfected into HC11 cells to determine whether

a shift in p92^{Brcal} could be detected. Although a shift in p210^{Brcal} was detected in response to treatment with DNA damaging agents, a shift in p92^{Brcal} in the same cells was not detected (Fig. 3C). These findings suggest that the inability to detect p92 phosphorylation in Brcal^{Δ11/Δ11} fibroblasts in response to DNA damage is likely to be intrinsic to this exon 11-deleted isoform.





Figure 3. p210^{Brcal} but not p92^{Brcal} undergoes a shift in response to DNA damage. A) Immunoblot analysis of p210^{Brcal} and p92^{Brcal} in cells treated with UV, γ-irradiation, or HU. p210^{Brcal} exhibits a dose-dependent shift in response to UV and gamma irradiation. HCl1 cells (top panel) or MEFs that express only p92^{Brcal} (bottom panel) were subject to identical treatments with UV, γ-irradiation, or HU. 20 μg of lysate was loaded per lane and immunoblotted with antibody mB1. B) Analysis of p210^{Brcal} phosphorylation in ³²P-orthophosphate labeled HCl1 cells treated with γ-irradiation (upper panel). Immediately following irradiation, HCl1 cells were incubated with 5 mCi of ³²P-orthophosphate for 1 hr. 3 mg of cell extract was used for immunoprecipitation with 10 μl of the IgG fraction of mB1 antibody. The resolution of this assay was not sufficient to detect a mobility shift of phosphorylated products. Identical treatment of Brcal^{Δ11/Δ11} MEFs irradiated with 20 Gy (lower panel). C) Immunoblot analysis of p210^{Brcal} and p92^{Brcal} in HCl1 cells treated with 200 J m⁻² UV. p210^{Brcal} and not p92^{Brcal} exhibits a dose-dependent shift.


Murine p210^{Brcal} and p92^{Brcal} Localize to Nuclear Foci. In order to determine if the lack of phosphorylation of p92^{Brcal} is due to

aberrant subcellular localization, biochemical fractionation of exponentially growing $Brcal^{\Delta 11/\Delta 11}$ fibroblasts was performed and nuclear and cytoplasmic fractions were analyzed by immunoblot analysis. To confirm the purity of these fractions, blots were probed with antisera specific for either α -tubulin or RAD50 as controls for cytoplasmic and nuclear proteins, respectively. Surprisingly, these studies revealed that p92Brcal was present in the nuclear fraction (Fig 4A). In order to confirm these results and to establish the subnuclear localization of p210Brcal and p92Brcal, immunofluorescence analysis (IF) was performed (Fig. 4C) since localization to nuclear foci during S phase is a cardinal feature of human BRCA1. Four independent antisera (mAb1-mAb4) raised against murine Brcal revealed that p210Brcal localizes to nuclear foci during S phase in both mammary epithelial cell and WT MEFs. Strikingly, when similar experiments were performed on fibroblasts using antisera directed against epitopes outside of exon 11, distinct nuclear foci were observed that were indistinguishable from those observed in HC11 mammary epithelial cells and wild type MEFs (Fig. 4C). Since $Brcal^{\Delta 11/\Delta 11}$ MEFs do not express p210^{Brcal}, we reasoned that any specific signal would be due to p92^{Brcal}. Consistent with this supposition, nuclear foci were not detected following IF using the exon 11-specific antisera mAb2 and mAb3. Notably, no signal was observed in the cytoplasm of HC11, WT MEFs, or $Brcal^{\Delta 11/\Delta 11}$ MEFs using any of the above antisera.

A



B



C





Figure 4. Localization of p210^{Brca1} and p92^{Brca1} to nuclear foci.
A) Western analysis of biochemical fractionation of *Brca1* ^{Δ 11/ Δ 11} MEFs. Equal volumes of nuclear and cytoplasmic extract were loaded per lane. Antibodies were used as described in Materials and Methods. B) Schematic of murine *Brca1* cDNA indicating regions against which antisera were raised. Numbers above the lines represent amino acid coordinates. C) Immunofluorescence analysis of *Brca1* subcellular localization. HCl1 cells, wild-type MEFs, and *Brca1* ^{Δ 11/ Δ 11} MEFs

were grown on microscope slides as described in Materials and Methods. Following permeabilization, S phase cells were incubated with affinity purified Brca1 antibodies at a concentration of 1 μ g/ml.

Association of Rad51 with p92^{Brca1} and Rad51 focus formation are compromised in Brca1 ^{Δ 11/ Δ 11} cells. The exon 11 region of human BRCA1 protein has been shown to be required for binding to RAD51. This observation suggested the possibility that p92^{Brca1} may not associate with Rad51 in Brca1 ^{Δ 11/ Δ 11} cells. To address this question, p92^{Brca1} was immunoprecipitated from extracts of Brca1 ^{Δ 11/ Δ 11} MEFs and analyzed by Western blotting with Rad51. Immunoblotting analysis revealed that Rad51 was detected in extracts derived from HC11 cells in which mAb1, mAb3, or mAb4 had been used to immunoprecipitate p210^{Brca1} (Fig. 5). In contrast, Rad51 was not detected in extracts derived from Brca1 ^{Δ 11/ Δ 11} MEFs that had been subjected to immunoprecipitation with the same anti-Brca1 antisera. In reciprocal coimmunoprecipitation experiments, p210^{Brca1} was detected in HC11 extracts immunoprecipitated with Rad51 antisera. However, it was not possible to determine if p92^{Brca1} was present in Rad51 immunoprecipitates due to the presence of a cross-reacting band that comigrated with p92^{Brca1} (data not shown).

A



B





Figure 5. Rad51 association with p92^{Brca1} is not detected in Brca1 ^{$\Delta 11/\Delta 11$} MEFs. Top panel. Extracts generated from cycling HC11 and Brca1 ^{$\Delta 11/\Delta 11$} MEFs were prepared as described in Materials and Methods. 1 mg of extract was used per sample for immunoprecipitation with 2 μ g of antibody. mAb1 and mAb3 were affinity purified. Rad51 antibody Ab-1 was used at 1:1000 for Western analysis. The cross-reacting faint band observed with mAb3 in Brca1 ^{$\Delta 11/\Delta 11$} MEFs does not comigrate with Rad51. Bottom panel. 7 mg of extract was used to detect association of p210^{Brca1} with Rad51. One quarter of extract immunoprecipitated with Rad51 Ab-1 is represented in lane 1. Immunoprecipitation of p92^{Brca1} from Brca1 ^{$\Delta 11/\Delta 11$} MEFs with affinity purified mAb4 does not reveal detectable Rad51 protein.

Rad51 has been shown to localize to subnuclear foci following treatment of cells with agents that induce double-stranded

breaks. The apparent lack of association of p92^{Brcal} with Rad51 prompted us to examine Rad51 focus formation in WT and Brcal^{Δ11/Δ11} MEFs. At 1, 3 and 6 hrs following irradiation with 10 Gy, Rad51 focus formation was assessed in cycling WT and Brcal^{Δ11/Δ11} MEFs by IF (Fig. 6). At 1 hr an average of 25 Rad51 foci were detected in WT cells treated with 10 Gy, whereas an average of only 6 foci per cell were detected following similar treatment in Brcal^{Δ11/Δ11} cells (Fig. 6B). In order to determine if Rad51 foci formation in Brcal^{Δ11/Δ11} MEFs was simply delayed rather than deficient, foci were also assessed 3 and 6 hrs following irradiation. The number of Rad51 foci in WT cells increased to 44 and 40 per cell at 3 and 6 hrs post-irradiation respectively, whereas Brcal^{Δ11/Δ11} MEFs averaged only 8 and 7 foci, respectively, at these same time points. Furthermore, impaired Rad51 formation was not due to decreased levels of Rad51 in Brcal^{Δ11/Δ11} MEFs as demonstrated by Western analysis of extracts from cells that had been treated in an identical manner as for immunofluorescence (Fig. 6C). Notably, the absence of p210^{Brcal} does not affect the previously demonstrated S phase-dependent expression of Rad51, suggesting that the inability to form foci is not due to aberrant cell cycle expression of Rad51 in Brcal^{Δ11/Δ11} cells (Fig. 2B). As a control, the number of Brcal foci was determined in WT and Brcal^{Δ11/Δ11} MEFs. This analysis revealed no significant differences in the numbers of Brcal foci present in WT vs. Brcal^{Δ11/Δ11} MEFs at 1, 3, or 6 hrs following irradiation with 10 Gy (Fig. 7A and B). In aggregate, these data suggest that p92^{Brcal} has a diminished ability to associate with Rad51, and that Rad51 focus formation is impaired in Brcal^{Δ11/Δ11} MEFs.

A



B




Figure 6. Impaired Rad51 foci formation in Brca1^{Δ11/Δ11} MEFs.

A) Representative Rad51 immunostained nuclei from WT and Brca1^{Δ11/Δ11} MEFs three hours following irradiation with 10 Gy. Cells were prepared for immunofluorescence using Rad51 antibody Ab-1 as described in Materials and Methods. Foci counts were obtained by visual inspection of 50 nuclei. B) Graph depicting numbers of foci per nucleus following irradiation with 10 Gy at 1 hr (p value = 9.1E-17) 3 hrs. (p value = 8.3E-51), and 6 hrs (p value = 1.5E-25). C) Rad51 levels do not change in response to irradiation in WT and Brca1^{Δ11/Δ11} MEFs. At the time points indicated following irradiation with 10 Gy, extracts were prepared at and

analyzed by immunoblotting as described in Materials and Methods.





Figure 7. *Brcal* Foci are present in irradiated *Brcal* ^{$\Delta 11/\Delta 11$} MEFs. A) Representative nuclei immunostained with mAb1. Cells were prepared for immunofluorescence as described in Materials and Methods. Foci counts were obtained by visual inspection of 10-15 nuclei. B) Graph depicting numbers of foci per nucleus following irradiation with 10 Gy at 1 hr (p

value = 0.54) 3 hrs. (p value = 0.55), and 6 hrs (p value = 0.24).

(6) Key Research Accomplishments

- Generation of four murine Brcal antisera.
- Demonstration that murine Brcal is cell cycle regulated and phosphorylated in response to DNA damage.
- Demonstration that the exon 11-deleted isoform of murine Brcal localizes to the nucleus.
- Demonstration that phosphorylation of murine exon 11-deleted Brcal is reduced as compared to full length Brcal.
- Demonstration that full length murine Brcal and exon 11-deleted Brcal localize to nuclear foci.
- Demonstration that association of Rad51 with exon 11-deleted Brcal is not detected.
- Demonstration that in response to γ -irradiation the formation of Rad51 foci in Brcal ^{Δ 11/ Δ 11} MEFs is significantly reduced.
- Demonstration that in response to γ -irradiation p92^{Brcal} forms foci in Brcal ^{Δ 11/ Δ 11} MEFs.

(7) Reportable Outcomes

- Generation of four murine Brcal antisera.
- Demonstration that murine Brcal is cell cycle regulated and phosphorylated in response to DNA damage.
- Demonstration that the exon 11-deleted isoform of murine Brcal localizes to the nucleus.
- Demonstration that phosphorylation of murine exon 11-deleted Brcal is reduced as compared to full length Brcal.
- Demonstration that full length murine Brcal and exon 11-deleted Brcal localize to nuclear foci.
- Demonstration that association of Rad51 with exon 11-deleted Brcal is not detected.
- Demonstration that in response to γ -irradiation the formation of Rad51 foci in Brcal ^{Δ 11/ Δ 11} MEFs is significantly reduced.
- Demonstration that in response to γ -irradiation p92^{Brcal} forms foci in Brcal ^{Δ 11/ Δ 11} MEFs.

(8) Conclusions

While human BRCA1 has been extensively characterized, little is currently known about its murine counterpart. In fact, the mouse Brcal protein shares only 58% sequence identity to human BRCA1, a finding that has contributed to the suggestion that these proteins may have different functions[2, 3]. In this report we characterize mouse Brcal protein and demonstrate that multiple features of the regulation, localization, and interactions of the mouse and human Brcal proteins are conserved. Similar to its human ortholog, mouse Brcal is cell cycle regulated and localizes to nuclear foci during S phase. In addition, mouse Brcal is phosphorylated in a dose-dependent manner in response to genotoxic agents suggesting that a similar kinase(s) exists in human and murine cells that is upstream of Brcal in a DNA damage response pathway. Like human BRCA1, murine Brcal also forms a complex with Rad51 consistent with experiments demonstrating that mouse Brcal functions in the repair of double-stranded breaks by homologous recombination[4]. In aggregate, these data further validate the use of mouse models to study BRCA1 function in human cells.

We have analyzed the expression of a naturally occurring Brcal isoform in fibroblasts derived from mouse embryos in which the exon 11 region of Brcal has been specifically deleted. Strikingly, we have found that p92^{Brcal} is localized to nuclear foci. This finding is consistent with our biochemical fractionation studies revealing that endogenous p92^{Brcal} is present in the nucleus, as well as with previous findings in human cells that anti-BRCA1 antibodies do not appear to detect cytoplasmic BRCA1 staining, despite the fact that p97^{BRCA1} and p110^{BRCA1} would otherwise be expected to be found in the cytoplasm. Our finding that exon 11-deleted isoforms of Brcal are also present in the nucleus raises for the first time the possibility that this isoform may partially compensate for mutations affecting Brcal, and may possess additional nuclear functions that are as of yet unrecognized.

Notably, our findings contrast with the cytoplasmic localization previously reported for human p97^{BRCA1} and p110^{BRCA1}, each of which lack the nuclear localization sequences reportedly required for nuclear transport of p220^{BRCA1}[5]. Nevertheless, the reported partial nuclear localization of human p110^{BRCA1} suggests that sequences other than the canonical BRCA1 nuclear localization sequences can be utilized for transport into the nucleus, or that exon 11-deleted isoforms of BRCA1 can be transported to the nucleus via binding to other nuclear proteins[6-8]. Such cryptic nuclear localization sequences may also be responsible for the nuclear localization of p92^{Brcal}.

Alternatively, the difference in localization between the mouse and human isoforms may be due to either cell type-specific differences, species-specific differences, or the nature of the assays employed for these studies. We favor the latter hypothesis. Whereas studies in human cells determined the subcellular localization of exogenously expressed p97^{BRCA1} and p110^{BRCA1} using transient transfection assays, we have determined the localization of the endogenous Brcal proteins. In this regard, previous reports have shown that the high levels of expression characteristic of transient transfection experiments may lead to mislocalization of BRCA1 to the cytoplasm[9]. Nevertheless, we cannot rule out the possibility that p92^{Brcal} may localize to the cytoplasm in cell types other than those examined here, or that human and mouse exon 11-deleted isoforms may localize differently.

Significantly, p210^{Brcal} displays a mobility shift indicative of phosphorylation in response to DNA damage, whereas p92^{Brcal} does not. Consistent with this, ³²P-labeling experiments failed to reveal a significant increase in phosphate incorporation in p92^{Brcal} in response to γ -irradiation suggesting that the inability to detect a shift is not due to a conformation of p92^{Brcal} that precludes altered mobility by SDS-PAGE. Diminished phosphorylation is also not due to defects in the activities of kinases that converge on Brcal since a DNA damage-induced mobility shift in p92^{Brcal} is not detected in HCl1 cells in which p210^{Brcal} does undergo a shift. Several kinases involved in cell cycle checkpoint control including ATM, Cds1, and ATR have been demonstrated to phosphorylate human BRCA1 *in vivo* in response to DNA damaging agents[10-13]. The observation that a putative Cds1 phosphorylation site present in mouse Brcal is located within exon 11 suggests that p92^{Brcal} may not be a target of Cds1. Moreover, a shift in the mobility of Cds1 protein by SDS-PAGE, which has been shown to correlate with kinase activation, occurs in both WT MEFs and Brcal ^{Δ 11/ Δ 11} MEFs following irradiation suggesting that the absence of p92^{Brcal} phosphorylation is not the result of an inactive Cds1 kinase [14-16]. In addition to an impaired response to γ -irradiation we were not able to detect a shift in p92^{Brcal} in response to HU or UV. Putative phosphorylation sites for ATR and ATM are present within exon 11 of Brcal and may explain, in part, the inability to detect phosphorylation of p92^{Brcal}. Alternatively, ATM or ATR phosphorylation of Brcal in response to DNA damage could be dependent on initial phosphorylation of serine 988 by Cds1 or the exon 11 region of Brcal may be required for binding to these kinases which may in turn be required for Brcal phosphorylation.

Our inability to detect a stable association between p92^{Brcal} and Rad51 in Brcal ^{Δ 11/ Δ 11} MEFs is consistent with results

demonstrating that RAD51 binds to the exon 11 region of human BRCA1[17]. We now provide evidence that this interaction may be required for the efficient formation of Rad51 foci in response to γ -irradiation, a finding that is consistent with evidence that Rad51 foci are reduced in embryonic stem cells harboring a similar *Brcal* mutation[18]. These data suggest that the inability to localize Rad51 may compromise the capacity of these cells to repair double-stranded breaks, thereby contributing to the defective G2/M checkpoint observed in response to ionizing radiation in these cells[19]. In human cells, the relocalization of RAD51 foci to sites of DNA damage has been shown to follow the formation of BRCA1 foci[20]. Our results suggest that in spite of the presence of p92^{Brcal} foci in *Brcal* ^{Δ 11/ Δ 11} MEFs, Rad51 focus formation is impaired suggesting that the exon 11 region is required for proper recruitment of Rad51. Nevertheless, while we have confirmed the previously reported association between p210^{Brcal} and Rad51 this interaction is non-stoichiometric and requires a substantial amount of extract to visualize. This is consistent with the observation that the interaction of human BRCA1 with RAD51 is indirect. In this regard, the demonstration that BRG-1, a component of the SWI/SNF complex, interacts directly with human BRCA1 through the exon 11 region is intriguing in that it suggests a model in which the chromatin-remodeling function of BRCA1 may be associated with its ability to mediate the proper assembly of RAD51[21].

Despite the shared properties of p210^{Brcal} and p92^{Brcal}, which suggest that exon 11-deleted isoforms may have nuclear functions, mouse knockout models clearly indicate that significant functional differences exist between full length and exon 11-deleted isoforms of *Brcal*. Foremost, mice engineered to express only p92^{Brcal} are not viable, and embryonic cells derived from these mice demonstrate hypersensitivity to γ -irradiation, defective G2-M checkpoint function, centrosome amplification, and genomic instability[19, 22, 23]. Moreover, cre-mediated excision of exon 11 of *Brcal* in epithelial cells of the murine mammary gland leads to abnormal ductal morphogenesis and tumor formation[24]. These experiments demonstrate that the exon 11 region is critical for normal *Brcal* function. In this context, our data suggest that the inability of p92^{Brcal} to provide G2-M checkpoint function, maintain genomic stability, and suppress tumorigenesis is not due to an inability of p92^{Brcal} to be transported to the nucleus, to localize to nuclear foci, or to be cell cycle regulated, but rather may be related to the inability of p92^{Brcal} to associate with Rad51 or other proteins such as BRG-1 and Rad50[25]. As such, our data suggesting that p92^{Brcal} is not phosphorylated in response to DNA damage imply that the signal transduction pathways activated by the replication checkpoint and

by lesions caused by UV-irradiation do not converge on the p92^{Brca1} protein. Accordingly, deletion of exon 11 of BRCA1 appears to impair its DNA damage-dependent phosphorylation, which may in turn affect the localization to nuclear foci or function of BRCA1-interacting proteins such as BARD1, BRCA2, or the RAD50/MRE11/NBS complex.

The naturally occurring expression of p92^{Brca1} during murine embryogenesis and in adult tissues suggests that exon 11-deleted isoforms may function in a variety of tissues. Moreover, in spite of a defect in γ -irradiation-induced Rad51 focus formation in cells lacking full length Brca1, analysis of Brca1 ^{Δ 11/ Δ 11} embryos suggests that p92^{Brca1} partially compensates for the lack of full length Brca1 during murine embryogenesis. The most striking evidence for this conclusion is the postnatal survival of targeted mouse lines in which only the p92^{Brca1} protein is predicted to be expressed[26]. Presumably this is due to interactions outside of the exon 11 region. In this regard, several proteins including BARD1, CtIP, and BAP, have been shown to interact with human BRCA1 through the amino and carboxyl terminal regions of the protein[27-30]. In addition to these functions, however, it is interesting to speculate that p92^{Brca1} may also have functions that are distinct from those of p210^{Brca1}.

(9) References

1. Rajan, J.V., et al., *Brca2 is coordinately regulated with Brca1 during proliferation and differentiation in mammary epithelial cells*. Proceedings of the National Academy of Sciences, USA, 1996. **93**: p. 13078-13083.
2. Abbott, D.W., et al., *BRCA1 expression restores radiation resistance in BRCA1-defective cancer cells through enhancement of transcription-coupled DNA repair*. Journal of Biological Chemistry, 1999. **274**(26): p. 18808-12.
3. Boyd, J., *BRCA1: more than a hereditary breast cancer gene? [news]*. Nat Genet, 1995. **9**(4): p. 335-6.
4. Moynahan, M., et al., *Brca1 controls homology-directed DNA repair*. Molecular Cell, 1999. **4**: p. 511-518.
5. Thakur, S., et al., *Localization of BRCA1 and a splice variant identifies the nuclear localization signal*. Molecular and Cellular Biology, 1997. **17**: p. 444-452.
6. Christophe, D., C. Christophe-Hobertus, and B. Pichon, *Nuclear targeting of proteins: how many different signals?* Cell Signal, 2000. **12**(5): p. 337-41.
7. Hood, J.K. and P.A. Silver, *In or out? Regulating nuclear transport*. Curr Opin Cell Biol, 1999. **11**(2): p. 241-7.
8. Moroianu, J., *Nuclear import and export pathways*. J Cell Biochem, 1999. **Suppl**(32-33): p. 76-83.
9. Wilson, C., et al., *Differential subcellular localization, expression and biological toxicity of BRCA1 and the splice variant BRCA1-delta11b*. Oncogene, 1997. **14**: p. 1-16.
10. Chen, J., *Ataxia telangiectasia-related protein is involved in the phosphorylation of BRCA1 following deoxyribonucleic acid damage*. Cancer Res, 2000. **60**(18): p. 5037-9.
11. Cortez, D., et al., *Requirement of ATM-dependent phosphorylation of Brca1 in the DNA damage response to double-strand breaks*. Science, 1999. **286**: p. 1162-1166.
12. Lee, J.S., et al., *hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response*. Nature, 2000. **404**(6774): p. 201-4.
13. Tibbetts, R.S., et al., *Functional interactions between BRCA1 and the checkpoint kinase ATR during genotoxic stress [In Process Citation]*. Genes Dev, 2000. **14**(23): p. 2989-3002.
14. Blasina, A., et al., *A human homologue of the checkpoint kinase Cds1 directly inhibits Cdc25 phosphatase*. Curr Biol, 1999. **9**(1): p. 1-10.

15. Brown, A.L., et al., A human Cds1-related kinase that functions downstream of ATM protein in the cellular response to DNA damage. *Proc Natl Acad Sci U S A*, 1999. **96**(7): p. 3745-50.
16. Matsuoka, S., M. Huang, and S.J. Elledge, Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. *Science*, 1998. **282**(5395): p. 1893-7.
17. Scully, R., et al., Association of BRCA1 with Rad51 in mitotic and meiotic cells. *Cell*, 1997. **88**: p. 265-275.
18. Bhattacharyya, A., et al., The Breast Cancer Susceptibility Gene BRCA1 Is Required for Subnuclear Assembly of Rad51 and Survival following Treatment with the DNA Cross-linking Agent Cisplatin. *J Biol Chem*, 2000. **275**(31): p. 23899-23903.
19. Xu, X., et al., Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. *Molecular Cell*, 1999. **3**(3): p. 389-95.
20. Paull, T.T., et al., A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage [In Process Citation]. *Curr Biol*, 2000. **10**(15): p. 886-95.
21. Bochar, D.A., et al., BRCA1 is associated with a human SWI/SNF-related complex: linking chromatin remodeling to breast cancer [In Process Citation]. *Cell*, 2000. **102**(2): p. 257-65.
22. Gowen, L.C., et al., Brcal deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities. *Nature Genetics*, 1996. **12**: p. 191-194.
23. Shen, S.X., et al., A targeted disruption of the murine Brcal gene causes gamma-irradiation hypersensitivity and genetic instability. *Oncogene*, 1998. **17**(24): p. 3115-24.
24. Xu, X., et al., Conditional mutation of Brcal in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation [see comments]. *Nature Genetics*, 1999. **22**(1): p. 37-43.
25. Zhong, Q., et al., Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response. *Science*, 1999. **285**(5428): p. 747-50.
26. Cressman, V., et al., Growth retardation, DNA repair defects, and lack of spermatogenesis in BRCA1-deficient mice. *Molecular and Cellular Biology*, 1999. **19**: p. 7061-7075.
27. Jensen, D.E., et al., BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. *Oncogene*, 1998. **16**(9): p. 1097-112.

Impaired DNA Damage Response in Cells Expressing an Exon 11-Deleted Murine Brca1 Variant That Localizes to Nuclear Foci

L. JULIE HUBER,¹ THOMAS W. YANG,¹ CHRISTOPHER J. SARKISIAN,¹ STEPHEN R. MASTER,¹
CHU-XIA DENG,² AND LEWIS A. CHODOSH^{1,3*}

*Department of Molecular & Cellular Engineering¹ and Division of Endocrinology, Diabetes and Metabolism,³
University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104-6160, and Genetics
of Development and Disease Branch, National Institute of Diabetes, Digestive, and Kidney Diseases,
National Institutes of Health, Bethesda, Maryland 20892²*

Received 7 September 2000/Returned for modification 23 October 2000/Accepted 27 March 2001

Both human and mouse cells express an alternatively spliced variant of BRCA1, BRCA1- Δ 11, which lacks exon 11 in its entirety, including putative nuclear localization signals. Consistent with this, BRCA1- Δ 11 has been reported to reside in the cytoplasm, a localization that would ostensibly preclude it from playing a role in the nuclear processes in which its full-length counterpart has been implicated. Nevertheless, the finding that murine embryos bearing homozygous deletions of exon 11 survive longer than embryos that are homozygous for *Brca1* null alleles suggests that exon 11-deleted isoforms may perform at least some of the functions of *Brca1*. We have analyzed both the full-length and the exon 11-deleted isoforms of the murine *Brca1* protein. Our results demonstrate that full-length murine *Brca1* is identical to human BRCA1 with respect to its cell cycle regulation, DNA damage-induced phosphorylation, nuclear localization, and association with Rad51. Surprisingly, we show that endogenous *Brca1*- Δ 11 localizes to discrete nuclear foci indistinguishable from those found in wild-type cells, despite the fact that *Brca1*- Δ 11 lacks previously defined nuclear localization signals. However, we further show that DNA damage-induced phosphorylation of *Brca1*- Δ 11 is significantly reduced compared to full-length *Brca1*, and that gamma irradiation-induced Rad51 focus formation is impaired in cells in which only *Brca1*- Δ 11 is expressed. Our results suggest that the increased viability of embryos bearing homozygous deletions of exon 11 may be due to expression of *Brca1*- Δ 11 and suggest an explanation for the genomic instability that accompanies the loss of full-length *Brca1*.

Germ line mutations in *BRCA1* predispose women to early-onset breast and ovarian cancers (18, 38). The *BRCA1* gene is composed of 23 exons that encode a 1,863-amino-acid full-length protein, over half of which is encoded by an unusually large exon, exon 11, which is 3.4 kb in length. In addition to the full-length BRCA1 protein, p220^{BRCA1}, human cells contain alternatively spliced variants referred to as BRCA1- Δ 11 (referred to here as p97^{BRCA1}) and BRCA1- Δ 11b (referred to here as p110^{BRCA1}), which lack all and most of exon 11, respectively (54, 58). These isoforms arise from in-frame splicing events and retain the highly conserved amino-terminal RING finger and carboxyl-terminal BRCT domains found in full-length BRCA1 but lack the nuclear localization signals previously identified in exon 11 (11, 54, 58). The abundant expression of p97^{BRCA1} and p110^{BRCA1} has been demonstrated in a variety of adult tissues, including the human mammary gland, in which transcripts encoding p110^{BRCA1} are expressed at levels comparable to those encoding p220^{BRCA1} (33, 54, 58).

The observation that human BRCA1 is phosphorylated in response to UV light, ionizing radiation, and other agents that damage DNA, and the identification of BRCA1-interacting proteins such as RAD51 and RAD50-Mre11-p95 complexes

that colocalize with BRCA1 following DNA damage have suggested a role for BRCA1 in DNA repair (49, 55, 56). Subsequent experiments have confirmed this suggestion by demonstrating that human and mouse *Brca1* are required for the repair of double-stranded DNA breaks (37, 51). BRCA1 has also been implicated in transcriptional regulation through the ability of its carboxyl-terminal domain to stimulate transcription in a variety of functional assays as well as by virtue of its demonstrated interaction with the nuclear proteins p53, pRB, CtIP, CBP/p300, ATF1, and RNA polymerase II holoenzyme complexes (2, 3, 10, 22, 26, 30, 35, 39, 40, 45–47, 63–65). In addition, the recent finding that BRCA1 is a component of a SWI/SNF-related complex suggests that BRCA1 may play a role in coordinating processes such as repair and transcription through the remodeling of chromatin (7).

Initial reports describing the subcellular localization of BRCA1 were highly controversial. BRCA1 has been reported by different groups to localize to the cytoplasm, to the nucleus, to cytoplasmic tube-like invaginations in the nucleus, or to be secreted (14, 28, 50; E. Coene, P. Van Oostveldt, K. Willems, J. van Emmelo, and C. R. De Potter, Letter, Nat. Genet. 16:122–124, 1997). These reports preceded experiments demonstrating functional roles for BRCA1 in DNA damage and transcription, each of which would have suggested that BRCA1 was likely to reside in the nucleus. Indeed, the subsequent observation that BRCA1 compartmentalizes to nuclear foci during S phase and undergoes a DNA damage-dependent dy-

* Corresponding author. Mailing address: Dept. of Molecular and Cellular Engineering, 612 Biomedical Res. Bldg II/III, University of Pennsylvania School of Medicine, 421 Curie Blvd., Philadelphia, PA 19104-6160. Phone: (215) 898-1321. Fax: (215) 573-6725. E-mail: chodosh@mail.med.upenn.edu.

namic redistribution served to focus efforts on experiments designed to identify a nuclear role for BRCA1 (48).

In contrast to BRCA1, the properties and functions of the exon 11-deleted isoforms of BRCA1 are largely unknown. Previous experiments suggesting that BRCA1- Δ 11 is localized to the cytoplasm were based on transient transfection protocols (54). Transient transfection methods have also been used to suggest that the murine counterpart to p110^{BRCA1} is localized predominantly in the cytoplasm (4). However, the fact that similar approaches indicated a cytoplasmic localization for p220^{BRCA1} suggests that determining the localization of exon 11-deleted isoforms will require examination of their endogenous expression patterns (58). Inconclusive results have been obtained regarding the cellular localization of p110^{BRCA1}; biochemical fractionation of transiently transfected cells has shown that p110^{BRCA1} is distributed equally between nuclear and cytoplasmic fractions, whereas immunofluorescence analysis of the same ectopically expressed protein was reported to yield exclusively cytoplasmic staining (58). These reports appear to be at odds with studies of endogenous BRCA1 proteins that use BRCA1 antibodies that recognize determinants shared by full-length BRCA1 and its isoforms, since these studies have generally failed to reveal the presence of BRCA1 proteins in the cytoplasm (50).

Notably, murine embryos bearing targeted mutations that selectively abolish expression of full-length *Brcal*, while leaving *Brcal*- Δ 11 expression intact, survive significantly longer than mice bearing targeted mutations that abolish expression of both *Brcal* and *Brcal*- Δ 11 (18, 20, 23, 31, 32, 52, 61). This finding suggests that in mouse cells *Brcal*- Δ 11 is able to partially compensate for the functions of full-length *Brcal*. Despite the decreased severity of their associated embryonic phenotype, embryonic cells derived from mice engineered to express only *Brcal*- Δ 11 exhibit hypersensitivity to gamma irradiation, defective G₂-M checkpoint function, centrosome amplification, and genomic instability (20, 52, 61). Furthermore, mice bearing mammary-specific deletions of exon 11 develop mammary adenocarcinomas with chromosomal instability (60). These data suggest that while *Brcal*- Δ 11 may partially compensate for *Brcal* function during embryogenesis, this naturally occurring isoform lacks the ability to maintain genomic stability and suppress tumorigenesis.

In this report, we demonstrate by biochemical fractionation and immunofluorescence that full-length and exon 11-deleted isoforms of murine *Brcal* are cell cycle regulated and compartmentalize to nuclear foci during S phase. We show that in contrast to full-length *Brcal*, *Brcal*- Δ 11 is not phosphorylated in response to DNA damage, is deficient in its ability to bind to Rad51, and is unable to promote the efficient formation of Rad51 foci. Taken together, these data suggest that *Brcal*- Δ 11 may provide some of the functions of full-length *Brcal* during murine embryogenesis but is unable to fully supplant the functions of full-length *Brcal* in the response to DNA damage.

MATERIALS AND METHODS

Generation of antisera. Regions encompassing amino acids 69 to 278 (mAb1), 809 to 1062 (mAb2), 995 to 1244 (mAb3), and 1365 to 1609 (mAb4) of the murine *Brcal* cDNA were subcloned into pGEX-6P-1 (Pharmacia). Lysates from *Escherichia coli* transformed with these constructs were passed over a glutathione-Sepharose column, and recombinant *Brcal* protein was cleaved from the

glutathione *S*-transferase polypeptide with PreScission Protease according to the manufacturer's instructions (Pharmacia). Antisera to purified *Brcal* polypeptides were raised in rabbits (Cocalico Biologicals) and were affinity purified according to published methods (24).

Cell culture, synchronization, and fractionation. HC11 cells were grown in RPMI medium containing 10% bovine calf serum. 5 μ g of insulin (Sigma) per ml, 10 ng of epidermal growth factor (Sigma) per ml, 2 mM L-glutamine, 100 U of penicillin per ml, and 100 μ g of streptomycin per ml. Mouse embryo fibroblasts (MEFs) were grown in Dulbecco modified Eagle medium containing 15% fetal bovine serum supplemented with 2 mM L-glutamine, 100 U of penicillin per ml, and 100 μ g of streptomycin per ml. 293T cells were grown in Dulbecco modified Eagle medium containing 10% bovine calf serum supplemented with 2 mM L-glutamine, 100 U of penicillin per ml, and 100 μ g of streptomycin per ml. 293T transfections employed the calcium phosphate method. HC11 cells were transfected using Eugene-6 (Roche Molecular Biochemicals). HC11 cells and fibroblasts were serum starved at 75% confluency and refed with regular growth media 48 h later. Cellular fractionation was performed according to the manufacturer's instructions with the NE-PER kit (Pierce).

Northern analysis, immunoblotting, and immunoprecipitation. Northern hybridization was performed as described previously using PCR-generated probes encompassing nucleotides 2541 to 3298 within exon 11 and nucleotides 4827 to 5354 within the carboxyl terminus of *Brcal* (43). Cell lysates for immunoblotting were prepared in 50 mM Tris (pH 8.0), 120 mM NaCl, and 0.05% Nonidet P-40 with 100 μ g of Pefabloc (Boehringer Mannheim Biochemicals) per ml, 20 μ g of aprotinin per ml, 10 μ g of leupeptin per ml, 0.1 mM β -glycerophosphate, 50 mM NaF, and 1 mM sodium orthovanadate. Samples were loaded onto sodium dodecyl sulfate-7% polyacrylamide gel electrophoresis (SDS-7% PAGE) gels with the exception of experiments designed to detect changes in the mobility of *Brcal*, for which 5 or 6% gels were run for extended periods. Wet transfer to nitrocellulose was performed overnight in a buffer containing 192 mM glycine, 25 mM Tris base, and 20% methanol. Membranes were blocked for 1 h in phosphate-buffered saline containing 5% nonfat dried milk and 0.5% Nonidet P-40. RAD51 Ab-1 (Calbiochem), RAD50 Clone 13 (Transduction Laboratories), and cyclin A H-432 (Santa Cruz Biotechnology) antibodies were each used at a 1:1,000 dilution in a blocking buffer for 1 h. β -Tubulin antibody N-357 (Amersham) was used at a 1:40,000 dilution. A peroxidase-conjugated goat anti-rabbit immunoglobulin G secondary antibody H+L (Jackson Immunoresearch) was used at a 1:3,000 dilution. Immunoprecipitations were performed for 1 h at 4°C. Rad51 antibodies Ab-1 (Oncogene Research) and I-20 and C-20 (Santa Cruz Biotechnology) and affinity-purified *Brcal* antibodies were employed at 2 μ g/ml. Immune complexes were precipitated with 20 μ l of protein A Sepharose and were washed five times with lysis buffer prior to the addition of 1 \times Laemmli sample buffer.

Treatment with DNA-damaging agents and orthophosphate labeling. Gamma irradiation was administered using a CIS bio international (IBL 437c) source. UV doses were administered using a Stratagene (Stratagene). Hydroxyurea (HU; Sigma) was used at a final concentration of 1 mM. Cells were lysed 1 h following treatment with genotoxic agents. For in vivo labeling experiments, gamma-irradiated cells were incubated with 5 mCi of [³²P]orthophosphate in serum-free medium immediately following dosing for 1 h prior to lysis and immunoprecipitation.

Immunofluorescence analysis. Cells were fixed and permeabilized according to published protocols (48). Affinity-purified *Brcal* antisera were used at a concentration of 2 μ g/ml. RAD51 (Ab-1) antisera were used at a 1:1,000 dilution. Tetramethyl rhodamine isothiocyanate-conjugated secondary antibody (Jackson Immunoresearch) was used at a dilution of 1:250. All images were obtained by laser scanning confocal microscopy.

RESULTS

Characterization of mouse *Brcal* antisera. Immunoblotting analysis of HC11 murine mammary epithelial cell extracts using murine *Brcal* antibodies mAb1, mAb2, mAb3, and mAb4 identified a specific band that migrated at a predicted molecular mass of 210 kDa and that was not recognized by preimmune sera (data not shown). To confirm that these antibodies recognize bona fide mouse *Brcal*, 293T cells were transfected with a mouse *Brcal* cDNA and lysates were prepared for immunoblotting. These studies revealed that polyclonal antibodies mAb1, mAb2, mAb3, and mAb4 each recognize a spe-




FIG. 1. Detection of mouse *Brca1* isoforms. (A) Immunoblot analysis demonstrating that mAb1, mAb2, and mAb4 recognize murine *Brca1*. Ten micrograms of either empty vector (pBKCMV) or pBKCMV*Brca1* (mAb1) and pcDNA3.1 or pcDNA3.1-m*Brca1* (mAb2 and mAb4) was introduced into 293T cells by calcium phosphate transfection. (–), empty vector; +, vector containing murine *Brca1* cDNA. Cell extracts were prepared 48 h following transfection, and 50 μ g of lysate was used for immunoblotting. Affinity-purified antibodies were employed at 1 μ g/ml. (B) Northern analysis demonstrating the absence of full-length *Brca1* transcripts in *Brca1*^{Δ11/Δ11} MEFs. Ten micrograms of poly(A) mRNA was loaded per lane. Probes encompassing exon 11-specific sequences (right panel; see Materials and Methods) and C-terminal sequences (left panel; see Materials and Methods) were derived by PCR amplification using the mouse *Brca1* cDNA as a template. (C) Immunoblot analysis of p210^{*Brca1*} expression in wild-type and *Brca1*^{Δ11/Δ11} MEFs. Fifty micrograms of cell extract per lane was probed with affinity-purified mAb1 at 1 μ g/ml. (D) mAb1 recognizes a predominant gene product of ~92 kDa in *Brca1*^{Δ11/Δ11} MEFs and 210 kDa in HC11 cells. Thirty micrograms of extract was loaded per lane. (E) p92^{*Brca1*} is expressed in testis and brain of wild-type mice. One hundred fifty micrograms of lysate per sample was subjected to SDS-PAGE on an 8% acrylamide gel. Δ11/+ Brain, tissue derived from a mouse heterozygous for the wild-type and exon 11-deleted alleles of *Brca1*.

cific band at the predicted molecular mass for mouse *Brca1* in extracts of *Brca1*-transfected 293T cells. (Fig. 1A and data not shown).

To determine if mAb1 could specifically recognize endogenous *Brca1*, extracts from wild-type MEFs and from MEFs derived from mice harboring a germ line deletion of the exon 11 region of *Brca1* were analyzed by immunoblotting (52). *Brca1*^{Δ11/Δ11} MEFs express an isoform of *Brca1* analogous to the naturally occurring human BRCA1 variant encoding p97^{BRCA1}. Northern analysis was performed using a probe encompassing nucleotides 4827 to 5354 that was predicted to recognize both the full-length and exon 11-deleted *Brca1* transcripts. As expected, a 3.9-kb transcript was detected in *Brca1*^{Δ11/Δ11} cells whereas a 7.2-kb transcript was detected in cells that express p210^{*Brca1*} (Fig. 1B, left panel). A similar analysis performed with a probe encompassing nucleotides 2541 to 3298 within exon 11 detected only the full-length *Brca1* transcript (Fig. 1B, right panel). Accordingly, immunoblotting of extracts prepared from wild-type MEFs revealed the presence of p210^{*Brca1*} whereas extracts prepared from *Brca1*^{Δ11/Δ11} MEFs did not, confirming that the 210-kDa polypeptide rec-

ognized by mAb1 is indeed *Brca1* (Fig. 1C). To determine if the putative protein encoded by the exon 11-deleted transcript is detectable in extracts derived from *Brca1*^{Δ11/Δ11} MEFs immunoblotting was performed. A major band of the predicted molecular mass, referred to here as p92^{*Brca1*}, was recognized by mAb1 antisera (Fig. 1D). This *Brca1* isoform was also detected in embryonic brain extracts prepared from embryos heterozygous for the exon 11-deleted allele of *Brca1*, as well as in extracts of testis and brain derived from wild-type mice. These findings demonstrate that p92^{*Brca1*} is a naturally occurring isoform of *Brca1* (Fig. 1E).

Full-length murine p210^{*Brca1*} and p92^{*Brca1*} are cell cycle regulated. Previous experiments have shown that murine *Brca1* mRNA expression is regulated in a cell cycle-dependent manner with maximal levels of *Brca1* occurring during the S phase of the cell cycle (43). Human BRCA1 mRNA and protein share this cell cycle-dependent pattern of expression consistent with a conserved S phase-specific function for the human and mouse *Brca1* proteins (13, 21, 44, 57). To determine if the protein expression pattern of *Brca1* parallels that of its mRNA, synchronization experiments were performed using HC11 mu-




FIG. 2. Mouse p210^{Brca1} and p92^{Brca1} are cell cycle regulated. (A) Immunoblot analysis of cell cycle regulation of p210^{Brca1}, cyclin A, and Rad51 in serum-starved HC11 cells. Active, exponentially growing cells. (B) Immunoblot analysis of cell cycle regulation of p92^{Brca1}, cyclin A, and Rad51 in serum-starved MEFs homozygous for the targeted deletion of exon 11. Cells were starved as described in Materials and Methods. Cells stimulated to reenter the cell cycle by refeeding were harvested at the time points indicated. Cell extracts were prepared as described in Materials and Methods, and 10 μ g of lysate was loaded per lane. Antibodies mAb1 and mAb2 revealed identical results in HC11 cells, whereas only mAb1 recognized a cell cycle-regulated band in *Brca1* ^{Δ 11/ Δ 11} MEFs (data not shown).

rine mammary epithelial cells. As shown in Fig. 2A, the mouse *Brca1* protein, p210^{Brca1}, is undetectable in serum-starved cells and becomes apparent when cells have progressed into the G₁ phase of the cell cycle approximately 8 h following addition of serum-containing media. Parallel experiments performed on *Brca1* ^{Δ 11/ Δ 11} fibroblasts demonstrated that the cell cycle-dependent expression pattern of p92^{Brca1} closely mimics that of p210^{Brca1}. Moreover, the temporal profile of p92^{Brca1} and p210^{Brca1} expression is similar to that of Rad51 and cyclin A, but contrasts with that of Rad50, which is expressed at relatively constant levels throughout the cell cycle.

Phosphorylation of p92^{Brca1} is not detected in response to DNA damage. The phosphorylation of human p220^{BRCA1} following treatment of cells with DNA-damaging agents was an early indication that human BRCA1 is involved in a DNA damage response pathway. Similarly, immunoblotting analysis of lysates generated from HC11 cells 1 h following treatment with UV, gamma radiation, or HU revealed a dose-dependent shift in the migration of full-length murine *Brca1* by SDS-PAGE (Fig. 3A, top panel). A complete shift of p210^{Brca1} similar to that described for human BRCA1 occurred in cells treated with 50 Gy.

[³²P]orthophosphate labeling of HC11 cells following treatment with 5 Gy demonstrated an increase in p210^{Brca1} labeling consistent with the supposition that, similar to human BRCA1, the observed mobility shift is due to phosphorylation (Fig. 3B, top panel). Exposure of cells to [³²P]orthophosphate has previously been shown to cause an increase in phosphorylation of human BRCA1 (55). Therefore, the basal levels of phosphorylation observed in unirradiated HC11 cells may be due either to the activation of a DNA damage response pathway by ³²P itself or to cell cycle-dependent phosphorylation of *Brca1*. Significantly, a shift in p92^{Brca1} was not observed in response to identical treatments with DNA-damaging agents, suggesting that this isoform may not be phosphorylated under these con-

ditions (Fig. 3A, bottom panel). This possibility was confirmed by [³²P]orthophosphate-labeling experiments in which increased phosphorylation of p92^{Brca1} was not detected following treatment of cells with 20 to 50 Gy (Fig. 3B, bottom panel, and data not shown).

Since the inability to detect a change in the phosphorylation status of p92^{Brca1} following DNA damage could be due to altered kinase signaling in *Brca1* ^{Δ 11/ Δ 11} fibroblasts rather than to properties specific to p92^{Brca1}, a p92^{Brca1} expression vector was transiently transfected into HC11 cells to determine whether a shift in p92^{Brca1} could be detected. Although a shift in p210^{Brca1} was detected in response to treatment with DNA-damaging agents, a shift in p92^{Brca1} in the same cells was not detected (Fig. 3C). These findings suggest that the inability to detect p92 phosphorylation in *Brca1* ^{Δ 11/ Δ 11} fibroblasts in response to DNA damage is likely to be intrinsic to this exon 11-deleted isoform.

Murine p210^{Brca1} and p92^{Brca1} localize to nuclear foci. In order to determine if the lack of phosphorylation of p92^{Brca1} is due to aberrant subcellular localization, biochemical fractionation of exponentially growing *Brca1* ^{Δ 11/ Δ 11} fibroblasts was performed and nuclear and cytoplasmic fractions were analyzed by immunoblot analysis. To confirm the purity of these fractions, blots were probed with antisera specific for either β -tubulin or RAD50 as controls for cytoplasmic or nuclear proteins, respectively. Surprisingly, these studies revealed that p92^{Brca1} was present in the nuclear fraction (Fig. 4A). In order to confirm these results and to establish the subnuclear localization of p210^{Brca1} and p92^{Brca1}, immunofluorescence analysis (IF) was performed (Fig. 4C) since localization to nuclear foci during S phase is a cardinal feature of human BRCA1 (48). Four independent antisera (mAb1-mAb4) raised against murine *Brca1* revealed that p210^{Brca1} localizes to nuclear foci during S phase in both mammary epithelial cell and wild-type MEFs. Strikingly, when similar experiments were performed




FIG. 3. p210^{Brca1} but not p92^{Brca1} undergoes a shift in response to DNA damage. (A) Immunoblot analysis of p210^{Brca1} and p92^{Brca1} in cells treated with UV, gamma irradiation, or HU. p210^{Brca1} exhibits a dose-dependent shift in response to UV and gamma irradiation. HC11 cells (top panel) or MEFs that express only p92^{Brca1} (bottom panel) were subjected to identical treatments with UV, gamma irradiation, or HU. Twenty micrograms of lysate was loaded per lane and immunoblotted with antibody mAb1. (B) Analysis of p210^{Brca1} phosphorylation in [³²P]orthophosphate-labeled HC11 cells treated with gamma irradiation (upper panel). Immediately following irradiation, HC11 cells were incubated with 5 mCi of [³²P]orthophosphate for 1 h. Three milligrams of cell extract was used for immunoprecipitation with 10 μl of the immunoglobulin G fraction of mAb1 antibody. The resolution of this assay was not sufficient to detect a mobility shift of phosphorylated products. *Brca1*^{Δ11/Δ11} MEFs irradiated with 20 Gy received identical treatment (lower panel). (C) Immunoblot analysis of p210^{Brca1} and p92^{Brca1} in HC11 cells treated with 200 J m⁻² UV. p210^{Brca1} and not p92^{Brca1} exhibits a dose-dependent shift.

on *Brca1*^{Δ11/Δ11} fibroblasts using antisera directed against epitopes outside of exon 11, distinct nuclear foci that were indistinguishable from those observed in HC11 mammary epithelial cells and wild-type MEFs were observed (Fig. 4C). Since *Brca1*^{Δ11/Δ11} MEFs do not express p210^{Brca1}, we reasoned that any specific signal would be due to p92^{Brca1}. Consistent with this supposition, nuclear foci were not detected following IF using the exon 11-specific antisera mAb2 and mAb3. Notably, no signal was observed in the cytoplasm of HC11, wild-type MEFs, or *Brca1*^{Δ11/Δ11} MEFs using any of the above antisera.

Association of Rad51 with p92^{Brca1} and Rad51 focus formation are compromised in *Brca1*^{Δ11/Δ11} cells. The exon 11 region of human BRCA1 protein has been shown to be required for binding to RAD51. This observation suggested the possibility that p92^{Brca1} may not associate with Rad51 in *Brca1*^{Δ11/Δ11} cells. To address this question, p92^{Brca1} was immunoprecipitated from extracts of *Brca1*^{Δ11/Δ11} MEFs and analyzed by Western blotting with Rad51. Immunoblotting analysis revealed that Rad51 was detected in extracts derived from HC11 cells in which mAb1, mAb3, or mAb4 had been used to immunoprecipitate p210^{Brca1} (Fig. 5). In contrast, Rad51 was not detected in extracts derived from *Brca1*^{Δ11/Δ11} MEFs that had been subjected to immunoprecipitation with the same anti-Brca1 antisera. In reciprocal coimmunoprecipitation experiments, p210^{Brca1} was detected in HC11 extracts immunoprecipitated with Rad51 antisera. However, it was not possible to determine if p92^{Brca1} was present in Rad51 immunoprecipitates due to the presence of a cross-reacting band that comigrated with p92^{Brca1} (data not shown).

Rad51 has been shown to localize to subnuclear foci follow-

ing treatment of cells with agents that induce double-stranded breaks (42). The apparent lack of association of p92^{Brca1} with Rad51 prompted us to examine Rad51 focus formation in wild-type and *Brca1*^{Δ11/Δ11} MEFs. At 1, 3, and 6 h following irradiation with 10 Gy, Rad51 focus formation was assessed in cycling wild-type and *Brca1*^{Δ11/Δ11} MEFs by IF (Fig. 6). At 1 h, an average of 25 Rad51 foci were detected in wild-type cells treated with 10 Gy, whereas an average of only 6 foci per cell were detected following similar treatment in *Brca1*^{Δ11/Δ11} cells (Fig. 6B). In order to determine if Rad51 focus formation in *Brca1*^{Δ11/Δ11} MEFs was simply delayed rather than deficient, foci were also assessed 3 and 6 h following irradiation. The numbers of Rad51 foci in wild-type cells increased to 44 and 40 per cell at 3 and 6 h postirradiation, respectively, whereas *Brca1*^{Δ11/Δ11} MEFs averaged only 8 and 7 foci, respectively, at these same time points. Furthermore, impaired Rad51 formation was not due to decreased levels of Rad51 in *Brca1*^{Δ11/Δ11} MEFs, as demonstrated by Western analysis of extracts from cells that had been treated in a manner identical to that used for immunofluorescence (Fig. 6C). Notably, the absence of p210^{Brca1} does not affect the previously demonstrated S phase-dependent expression of Rad51, suggesting that the inability to form foci is not due to aberrant cell cycle expression of Rad51 in *Brca1*^{Δ11/Δ11} cells (Fig. 2B) (19, 53, 62). As a control, the number of Brca1 foci was determined in wild-type and *Brca1*^{Δ11/Δ11} MEFs. This analysis revealed no significant differences in the numbers of Brca1 foci present in wild-type versus *Brca1*^{Δ11/Δ11} MEFs at 1, 3, or 6 h following irradiation with 10 Gy (Fig. 7). In aggregate, these data suggest that p92^{Brca1} has a diminished ability to associate with Rad51 and that Rad51 focus formation is impaired in *Brca1*^{Δ11/Δ11} MEFs.




FIG. 4. Localization of p210^{Brca1} and p92^{Brca1} to nuclear foci. (A) Western analysis of biochemical fractionation of *Brca1*^{Δ11Δ11} MEFs. Equal volumes of nuclear and cytoplasmic extract were loaded per lane. Antibodies were used as described in Materials and Methods. (B) Schematic of murine *Brca1* cDNA indicating regions against which antisera were raised. Numbers above the lines represent amino acid coordinates. (C) Immunofluorescence analysis of Brca1 subcellular localization. HC11 cells, wild-type MEFs, and *Brca1*^{Δ11Δ11} MEFs were grown on microscope slides as described in Materials and Methods. Following permeabilization, S phase cells were incubated with affinity-purified Brca1 antibodies at a concentration of 1 μg/ml.

DISCUSSION

While human BRCA1 has been extensively characterized, little is currently known about its murine counterpart. In fact, the mouse Brca1 protein shares only 58% sequence identity to human BRCA1, a finding that has contributed to the suggestion that these proteins may have different functions (1, 8). In this report, we characterize mouse Brca1 proteins and demonstrate that multiple features of the regulation, localization, and

interactions of the mouse and human Brca1 proteins are conserved. Similar to its human ortholog, mouse Brca1 is cell cycle regulated and localizes to nuclear foci during S phase. In addition, mouse Brca1 is phosphorylated in a dose-dependent manner in response to genotoxic agents suggesting that in human and murine cells there exists a similar kinase(s) that is upstream of Brca1 in a DNA damage response pathway. Like human BRCA1, murine Brca1 also forms a complex with




FIG. 5. Rad51 association with p92^{Brca1} is not detected in *Brca1*^{Δ11/Δ11} MEFs. (A) Extracts generated from cycling HC11 and *Brca1*^{Δ11/Δ11} MEFs were prepared as described in Materials and Methods. One milligram of extract was used per sample for immunoprecipitation with 2 μg of antibody. mAb1 and mAb3 were affinity purified. Rad51 antibody Ab-1 was used at 1:1,000 for Western analysis. The cross-reacting faint band observed with mAb3 in *Brca1*^{Δ11/Δ11} MEFs does not comigrate with Rad51. (B) Seven milligrams of extract was used to detect association of p210^{Brca1} with Rad51. One quarter of the extract immunoprecipitated with Rad51 Ab-1 is represented in lane 1. Immunoprecipitation of p92^{Brca1} from *Brca1*^{Δ11/Δ11} MEFs with affinity purified mAb4 does not reveal detectable Rad51 protein.

Rad51 consistent with experiments demonstrating that mouse *Brca1* functions in the repair of double-stranded breaks by homologous recombination (37). In aggregate, these data further validate the use of mouse models to study BRCA1 function in human cells.

We have analyzed the expression of a naturally occurring *Brca1* isoform in fibroblasts derived from mouse embryos in which the exon 11 region of *Brca1* has been specifically deleted. Strikingly, we have found that p92^{Brca1} is localized to nuclear foci. This finding is consistent with our biochemical fractionation studies revealing that endogenous p92^{Brca1} is present in the nucleus, as well as with previous findings that in human cells anti-BRCA1 antibodies do not appear to detect cytoplasmic BRCA1 staining, despite the fact that p97^{BRCA1} and p110^{BRCA1} would otherwise be expected to be found in the cytoplasm. Our finding that exon 11-deleted isoforms of *Brca1* are also present in the nucleus raises for the first time the possibility that this isoform may partially compensate for mutations affecting *Brca1* and may possess additional nuclear functions that are as of yet unrecognized.

Notably, our findings contrast with the cytoplasmic localization previously reported for human p97^{BRCA1} and p110^{BRCA1}, each of which lacks the nuclear localization sequences reportedly required for nuclear transport of p220^{BRCA1} (54). Never-

theless, the reported partial nuclear localization of human p110^{BRCA1} suggests that sequences other than the canonical *BRCA1* nuclear localization sequences can be utilized for transport into the nucleus or that exon 11-deleted isoforms of BRCA1 can be transported to the nucleus via binding to other nuclear proteins (15, 25, 36). Such cryptic nuclear localization sequences may also be responsible for the nuclear localization of p92^{Brca1}. Alternatively, the difference in localization between the mouse and human isoforms may be due to cell type-specific differences, to species-specific differences, or to the nature of the assays employed for these studies. We favor the last hypothesis. Whereas studies in human cells determined the subcellular localization of exogenously expressed p97^{BRCA1} and p110^{BRCA1} using transient transfection assays, we have determined the localization of the endogenous *Brca1* proteins. In this regard, previous reports have shown that the high levels of expression characteristic of transient transfection experiments may lead to mislocalization of BRCA1 to the cytoplasm (58). Nevertheless, we cannot rule out the possibilities that p92^{Brca1} may localize to the cytoplasm in cell types other than those examined here or that human and mouse exon 11-deleted isoforms may localize differently.

Significantly, p210^{Brca1} displays a mobility shift indicative of phosphorylation in response to DNA damage, whereas p92^{Brca1} does not. Consistent with this, ³²P-labeling experiments failed to reveal a significant increase in phosphate incorporation in p92^{Brca1} in response to gamma irradiation, suggesting that the inability to detect a shift is not due to a conformation of p92^{Brca1} that precludes altered mobility by SDS-PAGE. Diminished phosphorylation is also not due to defects in the activities of kinases that converge on *Brca1* since a DNA damage-induced mobility shift in p92^{Brca1} is not detected in HC11 cells in which p210^{Brca1} does undergo a shift. Several kinases involved in cell cycle checkpoint control including ATM, Cds1, and ATR have been demonstrated to phosphorylate human BRCA1 in vivo in response to DNA-damaging agents (12, 16, 29, 56). The observation that a putative Cds1 phosphorylation site present in mouse *Brca1* is located within exon 11 suggests that p92^{Brca1} may not be a target of Cds1. Moreover, a shift in the mobility of Cds1 protein by SDS-PAGE, which has been shown to correlate with kinase activation, occurs in both wild-type MEFs and *Brca1*^{Δ11/Δ11} MEFs following irradiation, suggesting that the absence of p92^{Brca1} phosphorylation is not the result of an inactive Cds1 kinase (data not shown) (6, 9, 34). In addition to an impaired response to gamma irradiation, we were not able to detect a shift in p92^{Brca1} in response to HU or UV. Putative phosphorylation sites for ATR and ATM are present within exon 11 of *Brca1* and may explain, in part, the inability to detect phosphorylation of p92^{Brca1}. Alternatively, ATM or ATR phosphorylation of *Brca1* in response to DNA damage could be dependent on initial phosphorylation of serine 988 by Cds1 or the exon 11 region of *Brca1* may be required for binding to these kinases which may in turn be required for *Brca1* phosphorylation (12).

Our inability to detect a stable association between p92^{Brca1} and Rad51 in *Brca1*^{Δ11/Δ11} MEFs is consistent with results demonstrating that RAD51 binds to the exon 11 region of human BRCA1 (49). We now provide evidence that this interaction may be required for the efficient formation of Rad51




FIG. 6. Impaired Rad51 foci formation in *Brca1* $\Delta 11/\Delta 11$ MEFs. (A) Representative Rad51 immunostained nuclei from wild-type and *Brca1* $\Delta 11/\Delta 11$ MEFs 3 h following irradiation with 10 Gy. Cells were prepared for immunofluorescence using Rad51 antibody Ab-1 as described in Materials and Methods. Foci counts were obtained by visual inspection of 50 nuclei. (B) Graph depicting numbers of foci per nucleus following irradiation with 10 Gy at 1 h (P value = 9.1×10^{-17}), 3 h (P value = 8.3×10^{-51}), and 6 h (P value = 1.5×10^{-25}). (C) Rad51 levels do not change in response to irradiation in wild-type and *Brca1* $\Delta 11/\Delta 11$ MEFs. At the time points indicated following irradiation with 10 Gy, extracts were prepared and analyzed by immunoblotting as described in Materials and Methods.

foci in response to gamma irradiation, a finding that is consistent with evidence that Rad51 foci are reduced in embryonic stem cells harboring a similar *Brca1* mutation (5). These data suggest that the inability to localize Rad51 may compromise the capacity of these cells to repair double-stranded breaks, thereby contributing to the defective G_2/M checkpoint observed in response to ionizing radiation in these cells (61). In human cells, the relocalization of RAD51 foci to sites of DNA damage has been shown to follow the formation of BRCA1 foci (41). Our results suggest that in spite of the presence of p92^{Brca1} foci in *Brca1* $\Delta 11/\Delta 11$ MEFs, Rad51 focus formation is impaired, suggesting that the exon 11 region is required for

proper recruitment of Rad51. Nevertheless, while we have confirmed the previously reported association between p210^{Brca1} and Rad51, this interaction is nonstoichiometric and requires a substantial amount of extract to visualize. This is consistent with the observation that the interaction of human BRCA1 with RAD51 is indirect (49). In this regard, the demonstration that BRG-1, a component of the SWI/SNF complex, interacts directly with human BRCA1 through the exon 11 region is intriguing in that it suggests a model in which the chromatin-remodeling function of BRCA1 may be associated with its ability to mediate the proper assembly of RAD51 (7).

Despite the shared properties of p210^{Brca1} and p92^{Brca1},




FIG. 7. *Brca1* Foci are present in irradiated *Brca1*^{Δ11/Δ11} MEFs. (A) Representative nuclei immunostained with mAb1. Cells were prepared for immunofluorescence as described in Materials and Methods. Foci counts were obtained by visual inspection of 10 to 15 nuclei. (B) Graph depicting numbers of foci per nucleus following irradiation with 10 Gy at 1 h (P value = 0.54), 3 h (P value = 0.55), and 6 h (P value = 0.24).

which suggest that exon 11-deleted isoforms may have nuclear functions, mouse knockout models clearly indicate that significant functional differences exist between full-length and exon 11-deleted isoforms of *Brca1*. Foremost, mice engineered to express only p92^{Brca1} are not viable, and embryonic cells derived from these mice demonstrate hypersensitivity to gamma irradiation, defective G₂-M checkpoint function, centrosome amplification, and genomic instability (20, 52, 61). Moreover, cre-mediated excision of exon 11 of *Brca1* in epithelial cells of the murine mammary gland leads to abnormal ductal morphogenesis and tumor formation (60). These experiments demonstrate that the exon 11 region is critical for normal *Brca1* function. In this context, our data suggest that the inability of p92^{Brca1} to provide G₂-M checkpoint function, maintain

genomic stability, and suppress tumorigenesis is not due to an inability of p92^{Brca1} to be transported to the nucleus, to localize to nuclear foci, or to be cell cycle regulated but rather may be related to the inability of p92^{Brca1} to associate with Rad51 or other proteins such as BRG-1 and Rad50 (66). As such, our data suggesting that p92^{Brca1} is not phosphorylated in response to DNA damage imply that the signal transduction pathways activated by the replication checkpoint and by lesions caused by UV irradiation do not converge on the p92^{Brca1} protein. Accordingly, deletion of exon 11 of *BRCA1* appears to impair its DNA damage-dependent phosphorylation, which may in turn affect the localization to nuclear foci or the function of *BRCA1*-interacting proteins such as BARD1, *BRCA2*, or the RAD50/MRE11/NBS complex.

The naturally occurring expression of p92^{Brcal} during murine embryogenesis and in adult tissues suggests that exon 11-deleted isoforms may function in a variety of tissues. Moreover, in spite of a defect in gamma irradiation-induced Rad51 focus formation in cells lacking full-length Brcal, analysis of Brcal^{Δ11/Δ11} embryos suggests that p92^{Brcal} partially compensates for the lack of full-length Brcal during murine embryogenesis. The most striking evidence for this conclusion is the postnatal survival of targeted mouse lines in which only the p92^{Brcal} protein is predicted to be expressed (17). Presumably this is due to interactions outside the exon 11 region. In this regard, several proteins including BARD1, CtIP, and BAP have been shown to interact with human BRCA1 through the amino- and carboxyl-terminal regions of the protein (27, 30, 59, 63). In addition to these functions, however, it is interesting to speculate that p92^{Brcal} may also have functions that are distinct from those of p210^{Brcal}.

ACKNOWLEDGMENTS

We thank members of the Chodosh laboratory and Prakash K. Rao for helpful discussions and critical reading of the manuscript. Confocal microscopy was made possible by the help of James F. Sanzo and Irina Chernysh of the Biomedical Imaging Core Facility at the University of Pennsylvania Medical Center.

This research was supported by NIH grants CA71513 and CA78410 from the National Cancer Institute, and U. S. Army Breast Cancer Research Program grants DAMD17-98-1-8230 (L.J.H.), DAMD17-96-1-6111 (S.R.M.), DAMD17-00-1-0403 (C.J.S.), DAMD17-98-1-8226, and DAMD17-96-1-6113.

REFERENCES

- Abbott, D. W., M. E. Thompson, C. Robinson-Benion, G. Tomlinson, R. A. Jensen, and J. T. Holt. 1999. BRCA1 expression restores radiation resistance in BRCA1-defective cancer cells through enhancement of transcription-coupled DNA repair. *J. Biol. Chem.* 274:18808-18812.
- Anderson, S. F., B. P. Schlegel, T. Nakajima, E. S. Wolpin, and J. D. Parvin. 1998. BRCA1 protein is linked to the RNA polymerase II holoenzyme complex via RNA helicase A. *Nat. Genet.* 19:254-256.
- Aprelikova, O., B. Fang, E. Meissner, S. Cotter, M. Campbell, A. Kuthiala, M. Bessho, R. Jensen, and E. Liu. 1999. BRCA1-associated growth arrest is RB-dependent. *Proc. Natl. Acad. Sci. USA* 96:11866-11871.
- Bachelier, R., N. Dalla Venezia, S. Mazoyer, L. Frappart, G. M. Lenoir, and A. Vincent. 2000. Differential expression and subcellular localization of murine BRCA1 and BRCA1-delta11 isoforms in murine and human cell lines. *Int. J. Cancer* 88:519-524.
- Bhattacharya, A., U. S. Ear, B. H. Koller, R. R. Weichselbaum, and D. K. Bishop. 2000. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. *J. Biol. Chem.* 275:23899-23903.
- Blasina, A., I. V. de Weyer, M. C. Laus, W. H. Luyten, A. E. Parker, and C. H. McGowan. 1999. A human homologue of the checkpoint kinase Cds1 directly inhibits Cdc25 phosphatase. *Curr. Biol.* 9:1-10.
- Bochar, D. A., L. Wang, H. Beniya, A. Kinev, Y. Xue, W. S. Lane, W. Wang, F. Kashanchi, and R. Shiekhattar. 2000. BRCA1 is associated with a human SWI/SNF-related complex: linking chromatin remodeling to breast cancer. *Cell* 102:257-265.
- Boyd, J. 1995. BRCA1: more than a hereditary breast cancer gene? *Nat. Genet.* 9:335-336.
- Brown, A. L., C. H. Lee, J. K. Schwarz, N. Mitiku, H. Pivnick-Worms, and J. H. Chung. 1999. A human Cds1-related kinase that functions downstream of ATM protein in the cellular response to DNA damage. *Proc. Natl. Acad. Sci. USA* 96:3745-3750.
- Chai, Y. L., J. Cui, N. Shao, E. Shyam, P. Reddy, and V. N. Rao. 1999. The second BRCT domain of BRCA1 proteins interacts with p53 and stimulates transcription from the p21WAF1/CIP1 promoter. *Oncogene* 18:263-268.
- Chen, C.-F., S. Li, Y. Chen, P.-L. Chen, Z. Sharp, and W.-H. Lee. 1996. The nuclear localization sequences of the BRCA1 protein interact with the importin-α subunit of the nuclear transport signal receptor. *J. Biol. Chem.* 271:32863-32868.
- Chen, J. 2000. Ataxia telangiectasia-related protein is involved in the phosphorylation of BRCA1 following deoxyribonucleic acid damage. *Cancer Res.* 60:5037-5039.
- Chen, Y., A. Farmer, C.-F. Chen, D. Jones, P.-L. Chen, and W.-H. Lee. 1996. BRCA1 is a 220-kDa nuclear phosphoprotein that is expressed and phosphorylated in a cell cycle-dependent manner. *Cancer Res.* 56:3168-3172.
- Chen, Y. M., C. F. Chen, D. J. Riley, D. C. Allred, P. L. Chen, D. Von Hoff, C. Osborne, and W.-H. Lee. 1995. Aberrant subcellular localization of BRCA1 in breast cancer. *Science* 270:789-791.
- Christophe, D., C. Christophe-Hobertus, and B. Pichon. 2000. Nuclear targeting of proteins: how many different signals? *Cell. Signal.* 12:337-341.
- Cortez, D., Y. Wang, J. Qin, and S. Elledge. 1999. Requirement of ATM-dependent phosphorylation of Brcal in the DNA damage response to double-strand breaks. *Science* 286:1162-1166.
- Cressman, V., D. Backlund, A. Avrutskaya, S. Leadon, V. Godfrey, and B. Koller. 1999. Growth retardation, DNA repair defects, and lack of spermatogenesis in BRCA1-deficient mice. *Mol. Cell. Biol.* 19:7061-7075.
- Easton, D., L. Steele, P. Fields, W. Ormiston, D. Averill, P. Daly, R. McManus, S. Neuhausen, D. Ford, R. Wooster, L. Cannon-Albright, M. Stratton, and D. Goldgar. 1997. Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. *Am. J. Hum. Genet.* 61:120-128.
- Flygare, J., F. Benson, and D. Heggren. 1996. Expression of the human RAD51 gene during the cell cycle in primary human peripheral blood lymphocytes. *Biochim. Biophys. Acta* 1312:231-236.
- Gowen, L. C., B. L. Johnson, A. M. Latour, K. K. Sulik, and B. Koller. 1996. Brcal deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities. *Nat. Genet.* 12:191-194.
- Gudas, J., T. Li, H. Nguyen, D. Jensen, F. I. Rauscher, and K. Cowan. 1996. Cell cycle regulation of BRCA1 messenger RNA in human breast epithelial cells. *Cell Growth Differ.* 7:717-723.
- Haile, D. T., and J. D. Parvin. 1999. Activation of transcription in vitro by the BRCA1 carboxyl-terminal domain. *J. Biol. Chem.* 274:2113-2117.
- Hakem, R., J. de la Pompa, C. Sirard, R. Mo, M. Woo, A. Hakem, A. Wakeham, J. Potter, A. Reitmair, F. Billia, E. Firpo, C. Hui, J. Roberts, J. Rossant, and T. Mak. 1996. The tumor suppressor gene Brcal is required for embryonic cellular proliferation in the mouse. *Cell* 85:1009-1024.
- Harlow, E., and D. Lane. 1999. Using antibodies: a laboratory manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
- Hood, J. K., and P. A. Silver. 1999. In or out? Regulating nuclear transport. *Curr. Opin. Cell Biol.* 11:241-247.
- Houvras, Y., M. Benezra, H. Zhang, J. J. Manfredi, B. L. Weber, and J. D. Licht. 2000. BRCA1 physically and functionally interacts with the ATF1 transcription factor. *J. Biol. Chem.* 275:36230-36237.
- Jensen, D. E., M. Proctor, S. T. Marquis, H. P. Gardner, S. I. Ha, L. A. Chodosh, A. M. Ishov, N. Tommerup, H. Vissing, Y. Sekido, J. Minna, A. Borodovsky, D. C. Schultz, K. D. Wilkinson, G. G. Maul, N. Barlev, S. L. Berger, G. C. Prendergast, and F. J. Rauscher III. 1998. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. *Oncogene* 16:1097-1112.
- Jensen, R., M. Thompson, T. Jetton, C. Szabo, R. van der Meer, B. Helou, S. Tronick, D. Page, M.-C. King, and J. Holt. 1996. BRCA1 is secreted and exhibits properties of a granin. *Nat. Genet.* 12:303-308.
- Lee, J. S., K. M. Collins, A. L. Brown, C. H. Lee, and J. H. Chung. 2000. hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response. *Nature* 404:201-204.
- Li, S., P. L. Chen, T. Subramanian, G. Chinnadurai, G. Tomlinson, C. K. Osborne, Z. D. Sharp, and W. H. Lee. 1999. Binding of CtIP to the BRCT repeats of BRCA1 involved in the transcription regulation of p21 is disrupted upon DNA damage. *J. Biol. Chem.* 274:11334-11338.
- Liu, C.-Y., A. Flesken-Nikitin, S. Li, Y. Zeng, and W.-H. Lee. 1996. Inactivation of the mouse Brcal gene leads to failure in the morphogenesis of the egg cylinder in early postimplantation development. *Genes Dev.* 10:1835-1843.
- Ludwig, T., D. L. Chapman, V. E. Papaioannou, and A. Efstratiadis. 1997. Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brcal, Brcal2, Brcal1/Brcal2, Brcal1/p53, and Brcal2/p53 nullizygous embryos. *Genes Dev.* 11:1226-1241.
- Magdiner, F., N. Dalla Venezia, G. M. Lenoir, L. Frappart, and R. Dante. 1999. BRCA1 expression during prenatal development of the human mammary gland. *Oncogene* 18:4039-4043.
- Matsuoka, S., M. Huang, and S. J. Elledge. 1998. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. *Science* 282:1893-1897.
- Monteiro, A., A. August, and H. Hanafusa. 1996. Evidence for a transcriptional activation function of BRCA1 C-terminal region. *Proc. Natl. Acad. Sci. USA* 93:13595-13599.
- Moroianu, J. 1999. Nuclear import and export pathways. *J. Cell. Biochem.* 32-33(Suppl):76-83.
- Moynahan, M., J. Chiu, B. Koller, and M. Jasin. 1999. Brcal controls homology-directed DNA repair. *Mol. Cell* 4:511-518.
- Narod, S. A., D. Ford, P. Devilee, R. B. Barkardottir, H. T. Lynch, S. A. Smith, B. A. Ponder, B. L. Weber, J. E. Garber, J. M. Birch, et al. 1995. An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Breast Cancer Linkage Consortium. *Am. J. Hum. Genet.* 56:254-264.
- Neish, A. S., S. F. Anderson, B. P. Schlegel, W. Wei, and J. D. Parvin. 1998. Factors associated with the mammalian RNA polymerase II holoenzyme. *Nucleic Acids Res.* 26:847-853.

40. Ouchi, T., S. W. Lee, M. Ouchi, S. A. Aaronson, and C. M. Horvath. 2000. Collaboration of signal transducer and activator of transcription 1 (STAT1) and BRCA1 in differential regulation of IFN-gamma target genes. *Proc. Natl. Acad. Sci. USA* 97:5208–5213.
41. Paull, T. T., E. P. Rogakou, V. Yamazaki, C. U. Kirchgessner, M. Gellert, and W. M. Bonner. 2000. A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. *Curr. Biol.* 10:886–895.
42. Raderschall, E., E. I. Golub, and T. Haaf. 1999. Nuclear foci of mammalian recombination proteins are located at single-stranded DNA regions formed after DNA damage. *Proc. Natl. Acad. Sci. USA* 96:1921–1926.
43. Rajan, J. V., M. Wang, S. T. Marquis, and L. A. Chodosh. 1996. Brca2 is coordinately regulated with Brca1 during proliferation and differentiation in mammary epithelial cells. *Proc. Natl. Acad. Sci. USA* 93:13078–13083.
44. Ruffner, H., and I. Verma. 1997. BRCA1 is a cell cycle-regulated nuclear phosphoprotein. *Proc. Natl. Acad. Sci. USA* 94:7138–7143.
45. Schlegel, B. P., V. J. Green, J. A. Ladias, and J. D. Parvin. 2000. BRCA1 interaction with RNA polymerase II reveals a role for hRPB2 and hRPB10alpha in activated transcription. *Proc. Natl. Acad. Sci. USA* 97:3148–3153.
46. Scully, R., S. Anderson, D. Chao, W. Wei, L. Ye, R. Young, D. Livingston, and J. Parvin. 1997. BRCA1 is a component of the RNA polymerase II holoenzyme. *Proc. Natl. Acad. Sci. USA* 94:5605–5610.
47. Scully, R., S. F. Anderson, D. M. Chao, W. Wei, L. Ye, R. A. Young, D. M. Livingston, and J. D. Parvin. 1997. BRCA1 is a component of the RNA polymerase II holoenzyme. *Proc. Natl. Acad. Sci. USA* 94:5605–5610.
48. Scully, R., J. Chen, R. Ochs, K. Keegan, M. Hoekstra, J. Feunteun, and D. Livingston. 1997. Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. *Cell* 90:425–435.
49. Scully, R., J. Chen, A. Plug, Y. Xiao, D. Weaver, J. Feunteun, T. Ashley, and D. Livingston. 1997. Association of BRCA1 with Rad51 in mitotic and meiotic cells. *Cell* 88:265–275.
50. Scully, R., S. Ganesan, M. Brown, J. A. De Caprio, S. Cannistra, J. Feunteun, S. Schnitt, and D. M. Livingston. 1996. Location of BRCA1 in human breast and ovarian cancer cells. *Science* 272:123–125.
51. Scully, R., S. Ganesan, K. Vlasakova, J. Chen, M. Socolovsky, and D. Livingston. 1999. Genetic analysis of BRCA1 function in a defined tumor cell line. *Mol. Cell* 4:1093–1099.
52. Shen, S. X., Z. Weaver, X. Xu, C. Li, M. Weinstein, L. Chen, X. Y. Guan, T. Ried, and C. X. Deng. 1998. A targeted disruption of the murine Brca1 gene causes gamma-irradiation hypersensitivity and genetic instability. *Oncogene* 17:3115–3124.
53. Tashiro, S., N. Kotomura, A. Shinohara, K. Tanaka, K. Ueda, and N. Kamada. 1996. S phase specific formation of the human Rad51 protein nuclear foci in lymphocytes. *Oncogene* 12:2165–2170.
54. Thakur, S., H. Zhang, Y. Peng, H. Le, B. Carroll, T. Ward, J. Yao, L. Farid, F. Couch, R. Wilson, and B. Weber. 1997. Localization of BRCA1 and a splice variant identifies the nuclear localization signal. *Mol. Cell. Biol.* 17:444–452.
55. Thomas, J., M. Smith, J. Tonkinson, B. Rubinfeld, and P. Polakis. 1997. Induction of phosphorylation on BRCA1 during the cell cycle and after DNA damage. *Cell Growth Differ.* 8:801–809.
56. Tibbetts, R. S., D. Cortez, K. M. Brumbaugh, R. Scully, D. Livingston, S. J. Elledge, and R. T. Abraham. 2000. Functional interactions between BRCA1 and the checkpoint kinase ATR during genotoxic stress. *Genes Dev.* 14:2989–3002.
57. Vaughn, J., P. Davis, M. Jarboe, G. Huper, A. Evans, R. Wiseman, A. Berchuck, J. Iglehart, P. Futreal, and J. Marks. 1996. BRCA1 expression is induced before DNA synthesis in both normal and tumor-derived breast cells. *Cell Growth Differ.* 7:711–715.
58. Wilson, C., M. Payton, G. Elliott, F. Buass, E. Cajulis, D. Grosshans, L. Ramos, D. Reese, D. Slamon, and F. Calzone. 1997. Differential subcellular localization, expression and biological toxicity of BRCA1 and the splice variant BRCA1-delta11b. *Oncogene* 14:1–16.
59. Wu, L. C., Z. W. Wang, J. T. Tsan, M. A. Spillman, A. Phung, X. L. Xu, M. C. Yang, L. Y. Hwang, A. M. Bowcock, and R. Baer. 1996. Identification of a RING protein that can interact in vivo with the BRCA1 gene product. *Nat. Genet.* 14:430–440.
60. Xu, X., K. U. Wagner, D. Larson, Z. Weaver, C. Li, T. Ried, L. Hennighausen, A. Wynshaw-Boris, and C. X. Deng. 1999. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. *Nat. Genet.* 22:37–43.
61. Xu, X., Z. Weaver, S. P. Linke, C. Li, J. Gotay, X. W. Wang, C. C. Harris, T. Ried, and C. X. Deng. 1999. Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. *Mol. Cell* 3:389–395.
62. Yamamoto, A., T. Taki, H. Yagi, T. Habu, K. Yoshida, Y. Yoshimura, K. Yamamoto, A. Matsushiro, Y. Nishimune, and T. Morita. 1996. Cell cycle-dependent expression of the mouse Rad51 gene in proliferating cells. *Mol. Gen. Genet.* 251:1–12.
63. Yu, X., L. C. Wu, A. M. Bowcock, A. Aronheim, and R. Baer. 1998. The C-terminal (BRCT) domains of BRCA1 interact in vivo with CtIP, a protein implicated in the CtBP pathway of transcriptional repression. *J. Biol. Chem.* 273:25388–25392.
64. Zhang, H., K. Somasundaram, Y. Peng, H. Tian, D. Bi, B. L. Weber, and W. S. El-Deiry. 1998. BRCA1 physically associates with p53 and stimulates its transcriptional activity. *Oncogene* 16:1713–1721.
65. Zheng, L., H. Pan, S. Li, A. Flesken-Nikitin, P. Chen, T. G. Boyer, and W. Lee. 2000. Sequence-specific transcriptional corepressor function for BRCA1 through a novel zinc finger protein, ZBRK1. *Mol. Cell* 6:757–768.
66. Zhong, Q., C. F. Chen, S. Li, Y. Chen, C. C. Wang, J. Xiao, P. L. Chen, Z. D. Sharp, and W. H. Lee. 1999. Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response. *Science* 285:747–750.